RecruitingPhase 2NCT06566586

A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Enrollment

80 participants

Start Date

Nov 6, 2024

Study Type

INTERVENTIONAL

Conditions

B-cell Lymphoma

Summary

To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing TQB3823 — a new targeted drug — in patients with relapsed or refractory B-cell lymphoma (a blood cancer), including both indolent (slow-growing) types and diffuse large B-cell lymphoma (DLBCL), to evaluate how safe and effective it is. **You may be eligible if...** - You are age 18–75 with a confirmed diagnosis of relapsed/refractory indolent B-cell lymphoma or DLBCL - You have received at least one prior line of standard treatment - You have at least one measurable tumor on imaging - Your major organ function (blood, liver, kidney) is adequate - You are in reasonable general health (ECOG 0–2) **You may NOT be eligible if...** - You have had another cancer within the past 3 years - Your lymphoma has spread to the brain (CNS involvement) - You have had a prior allogeneic (donor) stem cell transplant, or CAR-T therapy within 90 days - You are pregnant or breastfeeding - You have active hepatitis B/C or HIV Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTQB3702 tablets+Chemotherapy regimen

TQB3702 tablets: Tyrosine kinase inhibitor； Chemotherapy regimen：inhibiting tumor cell proliferation, suppressing DNA synthesis, inducing cell apoptosis, enhancing immune system function, and inhibiting angiogenesis；

Locations(30)

Cancer Hospital Chinise Academy of Medical Sciences

Beijing, Beijing Municipality, China

Gansu Provincial Cancer Hospital

Lanzhou, Gansu, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Guigang City People's Hospital

Guigang, Guangxi, China

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, China

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

PuYang AnYang District Hospital

Anyang, Henan, China

Puyang People's Hospital

Puyang, Henan, China

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University

Zhengzhou, Henan, China

Union Hosiptal, Tongji Medical College, Huazhong University of Science And Technolocy

Wuhan, Hubei, China

Tongji Hospital Tongji Medical College of HUST

Wuhan, Hubei, China

Xiangyang Central Hospital

Xiangyang, Hubei, China

Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

Changsha, Hunan, China

Zhuzhou Central Hospital

Zhuzhou, Hunan, China

The Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia, China

Jiangsu Provincial People's Hospital

Nanjing, Jiangsu, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

The second Hospital of dalian

Dalian, Liaoning, China

The Second Affiliated Hospital Of Xi'an Jiaotong University(Xibei Hospital)

Xi'an, Shaanxi, China

Affiliated Cancer Hospital of Shandong First Medical University

Jinan, Shandong, China

Tai'an Central Hospital

Tai’an, Shandong, China

Tongji Hospital of Tongji University

Shanghai, Shanghai Municipality, China

Shanxi Cancer Hospital

Taiyuan, Shanxi, China

The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, China

Zigong First People's Hospital

Zigong, Sichuan, China

Tianjin People's Hospital

Tianjin, Tianjin Municipality, China

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

Affiliated Tumor Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06566586

Related Trials

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT0663458950 locations

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT044913701 location

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

NCT062087357 locations

Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma

NCT073694921 location

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

NCT071621816 locations